|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
DE10043437A1
(de)
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US7741568B2
(en)
|
2005-01-13 |
2010-06-22 |
The Wiremold Company |
Downward facing receptacle assembly for cable raceway
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
KR101866623B1
(ko)
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 1가 항체 및 그의 제조 방법
|
|
EA015992B1
(ru)
|
2006-03-17 |
2012-01-30 |
Байоджен Айдек Эмэй Инк. |
Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
JP5397668B2
(ja)
|
2008-09-02 |
2014-01-22 |
ソニー株式会社 |
記憶素子および記憶装置
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
|
JP6002659B2
(ja)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
ヒトcd27に結合する抗体およびその使用
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CA2804550C
(en)
|
2010-07-09 |
2021-01-05 |
Bionovion Holding B.V. |
Agonistic antibody to cd27
|
|
WO2012023053A2
(en)
|
2010-08-16 |
2012-02-23 |
Novimmune S.A. |
Methods for the generation of multispecific and multivalent antibodies
|
|
BR112013002167A2
(pt)
|
2010-08-24 |
2016-05-31 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
CN102250246A
(zh)
|
2011-06-10 |
2011-11-23 |
常州亚当生物技术有限公司 |
抗VEGF/PDGFRβ双特异性抗体及其应用
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
US9527927B2
(en)
|
2011-12-20 |
2016-12-27 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
WO2014006217A1
(en)
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
KR20150058236A
(ko)
|
2012-08-20 |
2015-05-28 |
글리크닉 인코포레이티드 |
항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
|
|
BR112015007184A2
(pt)
|
2012-10-02 |
2017-08-08 |
Bristol Myers Squibb Co |
combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
|
|
MX387324B
(es)
|
2013-01-10 |
2025-03-18 |
Genmab Bv |
Variantes de regiones fc de igg1 de humano y usos de las mismas.
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
CN105682683A
(zh)
|
2013-08-02 |
2016-06-15 |
阿杜罗生物科技控股有限公司 |
结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CN106459165B
(zh)
|
2014-04-01 |
2021-04-20 |
拜恩科技细胞&基因治疗有限公司 |
密封蛋白-6特异性免疫受体和t细胞表位
|
|
JP2017513481A
(ja)
|
2014-04-16 |
2017-06-01 |
ユーシービー バイオファルマ エスピーアールエル |
多量体Fcタンパク質
|
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
MX392711B
(es)
|
2015-08-11 |
2025-03-24 |
Wuxi Biologics Ireland Ltd |
Anticuerpos anti-pd-1 novedosos.
|
|
JP6869987B2
(ja)
|
2015-09-01 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗pd−1抗体及びその使用方法
|
|
PL3368572T5
(pl)
|
2015-10-02 |
2026-07-20 |
Les Laboratoires Servier |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
EP3402255B1
(en)
|
2016-02-02 |
2021-03-31 |
Huawei Technologies Co., Ltd. |
Emission power verification method, user equipment, and base station
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
CN107286242B
(zh)
|
2016-04-01 |
2019-03-22 |
中山康方生物医药有限公司 |
抗pd-1的单克隆抗体
|
|
EP3848393A1
(en)
|
2016-05-18 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Antibody molecules for cancer treatment
|
|
US20190185571A1
(en)
|
2016-07-28 |
2019-06-20 |
Musc Foundation For Research Development |
Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
|
|
EP3497120A1
(en)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN107840887B
(zh)
|
2016-09-21 |
2022-03-25 |
基石药业(苏州)有限公司 |
一种新的pd-1单克隆抗体
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
EP3535291A1
(en)
|
2016-11-01 |
2019-09-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
WO2018103017A1
(zh)
|
2016-12-07 |
2018-06-14 |
深圳市大疆创新科技有限公司 |
无人机的控制方法及无人机
|
|
CN107058315B
(zh)
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
|
US11566060B2
(en)
|
2017-01-05 |
2023-01-31 |
Kahr Medical Ltd. |
PD1-CD70 fusion protein and methods of use thereof
|
|
EP3565839A4
(en)
|
2017-01-05 |
2021-04-21 |
Gensun Biopharma Inc. |
CHECKPOINT REGULATOR ANTAGONISTS
|
|
BR112019015900A2
(pt)
|
2017-02-10 |
2020-04-07 |
Genmab B.V. |
polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
WO2019000146A1
(zh)
|
2017-06-26 |
2019-01-03 |
深圳市博奥康生物科技有限公司 |
一种人程序性死亡受体1基因的siRNA及其应用
|
|
US12649798B2
(en)
|
2018-01-24 |
2026-06-09 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
KR20210011919A
(ko)
*
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
JP7513530B2
(ja)
|
2018-06-22 |
2024-07-09 |
ジェンマブ ホールディング ビー.ブイ. |
抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法
|
|
WO2021156326A1
(en)
|
2020-02-04 |
2021-08-12 |
Genmab A/S |
Antibodies for use in therapy
|
|
WO2022089377A1
(en)
*
|
2020-10-26 |
2022-05-05 |
Taizhou Eoc Pharma Co., Ltd. |
Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
|
|
AR127743A1
(es)
*
|
2021-09-06 |
2024-02-28 |
Genmab Bv |
Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
|